← Back to Search

Pharmacogenetic Testing

Genetic-Guided Medication for Mental Health Disorders in Children (PGx-SParK Trial)

N/A

Recruiting

Led By Chad Bousman, PhD

Research Sponsored by University of Calgary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Treating psychiatrist, family physician, or pediatrician licensed in Alberta, British Columbia, Saskatchewan, or Manitoba requests pharmacogenetic testing

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6-months

Awards & highlights

PGx-SParK Trial Summary

This trial tests whether using genetic information can help tailor psychiatric medication to individual children and adolescents.

Who is the study for?

This trial is for children and adolescents aged 6-24 in Alberta, British Columbia, Saskatchewan, or Manitoba who are starting or changing psychiatric medication. They must have medical records available and a licensed psychiatrist or physician requesting the test. Those with unstable health conditions, inability to consent, reluctance to give a saliva sample, or history of certain transplants cannot join.Check my eligibility

What is being tested?

The study is testing whether using pharmacogenetic testing (looking at how genes affect a person's response to drugs) can help in prescribing the right psychiatric medications for kids when they're either starting new meds or adjusting current ones.See study design

What are the potential side effects?

Since this trial involves genetic testing rather than drug administration, there are no direct side effects from interventions like you would expect with medications. However, there may be indirect consequences related to personal data handling and potential psychological impact.

PGx-SParK Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My doctor in Alberta, BC, Saskatchewan, or Manitoba has requested a genetic test for my medication.

PGx-SParK Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6-months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6-months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse drug reactions

Symptom severity

Secondary outcome measures

Healthcare utilization

PGx-SParK Trial Design

1Treatment groups

Experimental Treatment

Group I: Pharmacogenetic TestingExperimental Treatment1 Intervention

Pharmacogenetic testing panel (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, NUDT15, SLCO1B1, TPMT, VKORC1)

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor

792 Previous Clinical Trials

863,154 Total Patients Enrolled

Chad Bousman, PhDPrincipal InvestigatorUniversity of Calgary

2 Previous Clinical Trials

572 Total Patients Enrolled

Media Library

Pharmacogenetic Testing (Pharmacogenetic Testing) Clinical Trial Eligibility Overview. Trial Name: NCT04797364 — N/A

Mental Health Disorder Research Study Groups: Pharmacogenetic Testing

Mental Health Disorder Clinical Trial 2023: Pharmacogenetic Testing Highlights & Side Effects. Trial Name: NCT04797364 — N/A

Pharmacogenetic Testing (Pharmacogenetic Testing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04797364 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals who exceed the age of 35 years permitted to participate in this experiment?

"This trial's parameters dictate that those enrolling are aged 6 to 24. There are also specialized clinical trials for patients under 18 and above 65 years old, with 6 studies dedicated to the former and 5 devoted to the latter demographic."

Answered by AI

Which individuals are the most suitable candidates for participating in this experiment?

"The researchers of this clinical trial are searching for a pool of 6000 individuals aged between 6 and 24 who suffer from mental health issues. Furthermore, the necessary qualifications to be included as a participant include: accessible medical records, an Alberta or British Columbia licensed family physician/psychiatrist/pediatrician requesting pharmacogenetic testing; indications that psychiatric medications need to commence, change dose or augment treatment regimens."

Answered by AI

What is the aggregate number of individuals participating in this research?

"Affirmative. The clinical trial database confirms that this investigation is actively looking for participants, beginning from the 18th of January 2021 and last updated on 3rd November 2022. In total, 6000 patients are sought at a single institution."

Answered by AI

Are any new participants being sought for this clinical research endeavor?

"Affirmative. According to clinicaltrials.gov, this medical trial was initially posted on January 18th 2021 and is currently in search of 6000 individuals from a single site. It has been most recently updated on November 3rd 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pharmacogenetic Supported Prescribing in Kids

Chad Bousman 2021. "Pharmacogenetic Supported Prescribing in Kids". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04797364.